Kidney Week

Educational Symposium

Novel Therapeutic Options in Hyperkalemia

October 25, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Hyperkalemia is a common clinical challenge when treating patients with CKD. In addition to the acute management that is required, recurrent hyperkalemia limits the use of such proven therapies as RAAS inhibitors.

This symposium provides an update on recent advances in the treatment of acute and chronic hyperkalemia. In addition to the epidemiology of hyperkalemia, discussion includes the clinical use of novel potassium-lowering agents.

Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

Learning Objective(s)

• Describe the incidence, risk factors, and adverse outcomes associated with hyperkalemia
• Discuss treatment options for hyperkalemia, including the efficacy and safety of novel agents
• Describe therapeutic strategies that can minimize hyperkalemia as a barrier to the use of proven regimens that lower the risk of cardiovascular and kidney diseases

Learning Pathway(s)

• Bone and Mineral Metabolism
• Chronic Kidney Disease

Moderator

• Niraj Desai, MD

Presentations

• Introduction
  01:00 PM - 01:10 PM
  Niraj Desai, MD 
  
  

  Niraj Desai, MD

  Dr. Desai is an Assistant Professor of Nephrology and Hypertension at Case Western Reserve University School of Medicine. He is currently the Chief of Nephrology at the Louis Stokes Cleveland VA Medical Center and is an Associate Program Director for both the Internal Medicine Residency Program and Nephrology Fellowship Program at Case Western Reserve University/University Hospitals Cleveland Medical Center.

Introduction

October 25, 2020 | 01:00 PM - 01:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Risk Factors and Outcomes of Hyperkalemia
  01:10 PM - 01:35 PM
  

Risk Factors and Outcomes of Hyperkalemia

October 25, 2020 | 01:10 PM - 01:35 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• New Therapeutic Options in Hyperkalemia
  01:35 PM - 02:00 PM
  Faiez Zannad, MD, PhD 
  

  Faiez Zannad, MD, PhD

  Faiez Zannad MD, Cardiologist, PhD in clinical pharmacology (Université de Lorraine, Nancy, Université Claude Bernard, Lyon, France and Oxford MRC, UK). Professor Emeritus of Therapeutics at the Université of Lorraine, Past Director of the Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. 2019 Eugene Braunwald Scolar at Harvard Medical School. He has significantly contributed to building the evidence supporting modern HF therapy, including mineralocorticoid receptor antagonists, beta-blockers, and anticoagulants, as well as in major comorbid conditions in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, and chronic kidney disease. He recently led 2 important European Union granted research programs on omics biomarkers (HOMAGE) and fibrosis as a biological target (FIBROTARGETS). Past Chairman of the French Society of Hypertension, of the European Society of Cardiology (ESC) Working Group on Pharmacology and Drug Therapy. Founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, a think tank meeting dedicated to the science of clinical trials, with meetings in Paris, Washington DC, in Asia and the Middle East. He published more than 820 peer-reviewed papers (as per August 2020, h-Index = 118), and several books and book chapters. He is section editor of the ESC Textbook. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA.

New Therapeutic Options in Hyperkalemia

October 25, 2020 | 01:35 PM - 02:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.